CF News Today's Monthly Round Up

Stay connected to the latest news and perspectives on cystic fibrosis. See below for a selection of recent, popular news stories and patient columns:

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data Vertex Seeks to Expand FDA Approval of CFTR Modulators to Include More Mutations Moderna, Vertex Team Up to Develop Gene-editing Delivery Techniques Listening to Both Sides of the Mask Debate Savara Closing Trial of Molgradex in Treating NTM Lung Infections in CF Patients EMA Validates Application Seeking Expansion of Kaftrio Approval

Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is safe for use in children with cystic fibrosis (CF) as young as age 6, data from a global Phase 3 clinical trial show.[...]

Keep Reading

Vertex Seeks to Expand FDA Approval of CFTR Modulators to Include More Mutations The U.S. Food and Drug Administration (FDA) is reviewing applications from Vertex Pharmaceuticals to expand the approval for three of the company’s cystic fibrosis[...]

Keep Reading

Moderna, Vertex Team Up to Develop Gene-editing Delivery Techniques Moderna Therapeutics and Vertex Pharmaceuticals have entered a three-year research and licensing agreement aimed at developing gene-editing delivery techniques for the treatment of cystic fibrosis[...]

Keep Reading

Listening to Both Sides of the Mask Debate “I want to take my mask off.” I said these words to my daughters two days ago in a Barnes & Noble bookstore, even though I have pontificated novels to the contrary since this novel virus hit.[...]

Keep Reading

Savara Closing Trial of Molgradex in Treating NTM Lung Infections in CF Patients Savara Pharmaceuticals is stopping its Phase 2a exploratory clinical study of Molgradex (molgramostim nebulizer solution) to treat nontuberculous mycobacterial (NTM) lung infection in people[...]

Keep Reading

EMA Validates Application Seeking Expansion of Kaftrio Approval The European Medicines Agency (EMA) has validated an application that seeks to expand the approval of Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with[...]

Keep Reading